

After the Abstract, replace Sequence Listing pages 1-3, filed August 21, 2000, with Sequence Listing pages 1-13 submitted herewith.

OK

IN THE CLAIMS

Cancel

Replace pending claims 4, 6, 7, 9-12 and 14-16 with the following claims. Applicants have attached a separate sheet (Appendix A) showing the amendments.

-OK

4. (Amended) A protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 4 (partial structural protein of Ljungan 145SL)

Lys Asp Leu Met Glu Ile Ala Arg Met Pro Ser Val Tyr Lys Gly Glu
5 10 15
15 Arg Thr Glu Pro Gly Gly Thr Asn Gly Tyr Phe Gln Trp Ser His Thr
20 25 30
His Ser Pro Ile Asn Trp Val Phe Asp Gly Gly Ile His Leu Glu Asp
35 40 45
Met Pro Asn Leu Asn Leu Phe Ser Ser Cys Tyr Asn Tyr Trp Arg Gly
20 50 55 60
Ser Thr Val Leu Lys Leu Thr Val Tyr Ala Ser Thr Phe Asn Lys Gly
65 70 75 80
Arg Leu Arg Met Ala Phe Phe Pro Ile Met Met Gln Gly Thr Gln Arg
85 90 95
25 Lys Lys His Lys Cys Leu Phe Met Val Cys Asp Ile Gly Leu Asn Asn
100 105 110
Thr Phe Glu Met Thr Ile Pro Tyr Thr Trp Gly Asn Trp Met Arg Pro
115 120 125
Thr Arg Gly Ser Val Ile Gly Trp Leu Arg Ile Asp Val Leu Asn Arg
30 130 135 140
Leu Thr Tyr Asn Ser Ser Ser Pro Asn Ala Val Asn Cys Ile Leu Gln
145 150 155 160
Val Lys Met Gly Asn Asp Ala Lys Phe Met Val Pro Thr Thr Ser Asn
165 170 175
35 Ile Val Trp ,

01 and homologous sequences having at least 75% homology to the SEQ ID NO: 4, and antigenic fragments of the sequences.

02 7. (Twice amended) A diagnostic kit comprising a protein according to claim 4 or claim 17 or an antibody-binding part thereof.

03 9. (Amended) The vaccine according to claim 15 or 18, which additionally comprises an adjuvant.

04 11. (Twice amended) A pharmaceutical composition for treating or preventing infection by a virus in a mammal, said virus comprising in the non-coding region of its viral genome a nucleotide sequence corresponding to a cDNA sequence selected from the group consisting of SEQ ID NO: 1 and sequences at least 75% homologous to SEQ ID NO: 1, said pharmaceutical composition comprising a protein according to claim 4 or claim 17 or an antibody-binding part thereof.

15. (Amended) A vaccine having as an immunizing or neutralizing component a protein according to claim 4 or claim 17 or an antibody-binding part thereof.

05 16. (Amended) A method for preventing or treating infection in a mammal, including a human, by a virus comprising in the non-coding region of its viral genome a nucleotide sequence corresponding to a cDNA sequence selected from the group consisting of SEQ ID NO: 1 and sequences at least 75% homologous to SEQ ID NO: 1, said method comprising administering to said mammal a prophylactically or therapeutically effective amount of a composition selected from the group consisting of:

(a) a protein according to claim 4 or claim 17 or an antibody-binding part thereof;

OS (b) a pharmaceutical composition according to claim 11; and

(c) a vaccine according to any one of claims 9, 15 or 18.

17. A protein according to claim 4, comprising an antigen.

Q6 18. The vaccine according to claim 15, said vaccine additionally comprising a subunit of a virus, said virus comprising in the non-coding region of its viral genome a nucleotide sequence corresponding to a cDNA sequence selected from the group consisting of SEQ ID NO: 1 and sequences at least 75% homologous to SEQ ID NO: 1.

~~19. The method according to claim 16, wherein the pharmaceutical composition additionally comprises a subunit of the virus.~~

REMARKS

Applicant has amended the specification to insert SEQ ID NOS. on pages 11 (Table 2) and 12 and has replaced Sequence Listing pages 1-3, filed August 21, 2000 with new Sequence Listing pages 1-13.

Applicant has amended claims 4, 7, 9, 11 and 15-16, canceled claims 6, 10, 12 and 14, without prejudice, and added claims 17-19. Applicant expressly reserves the right to prosecute the subject matter of the canceled claims in one or more further applications that claim priority under 35 U.S.C. § 120 from this application. Upon entry of the amendments,